Bausch Health Stock Halted After Patent Ruling. The Decision Could Be the ‘Worst Possible Outcome,’ Analyst Says.

A federal court ruling has dealt a blow to Bausch Health by appearing to clear the way for generic competition for the company’s drug Xifaxan.

Bausch Health stock (ticker: BHC) plummeted more than 50% Thursday morning on the news, and trading of the shares was halted.

 » Read More  » Read More

Tags: No tags

Comments are closed.